MARKET

BCDA

BCDA

Biocardia Inc
NASDAQ
2.800
+0.120
+4.48%
After Hours: 2.760 -0.04 -1.43% 19:52 03/28 EDT
OPEN
2.705
PREV CLOSE
2.680
HIGH
2.950
LOW
2.580
VOLUME
143.66K
TURNOVER
--
52 WEEK HIGH
6.41
52 WEEK LOW
1.625
MARKET CAP
13.10M
P/E (TTM)
-0.6629
1D
5D
1M
3M
1Y
5Y
1D
BIOCARDIA REPORTS 2024 BUSINESS HIGHLIGHTS AND FINANCIAL RESULTS
Reuters · 3d ago
Weekly Report: what happened at BCDA last week (0317-0321)?
Weekly Report · 5d ago
BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025
Barchart · 03/21 07:30
Weekly Report: what happened at BCDA last week (0310-0314)?
Weekly Report · 03/17 11:25
Weekly Report: what happened at BCDA last week (0303-0307)?
Weekly Report · 03/10 11:27
BioCardia Announces Japanese Patent for Helix™ Biotherapeutic Delivery System
Barchart · 03/10 08:15
Director’s Bold Move: Major Stock Purchase Signals Confidence in BioCardia
TipRanks · 03/06 02:15
Weekly Report: what happened at BCDA last week (0224-0228)?
Weekly Report · 03/03 11:26
More
About BCDA
More
BioCardia, Inc. is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. It is advancing two cell therapy platforms derived from bone marrow such as CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being advanced as a cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS). Its autologous CardiAMP and allogeneic CardiALLO cell therapies intended for cardiac indications of HFrEF and CMI are enabled by its Helix minimally invasive intramyocardial therapeutic delivery platform.
Recently
Symbol
Price
%Change

Webull offers BioCardia Inc stock information, including NASDAQ: BCDA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BCDA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BCDA stock methods without spending real money on the virtual paper trading platform.